AÉMA-GROUPE
30.9.2021 14:15:05 CEST | Business Wire | Press release
On 30 September 2021, Aéma Groupe acquired Aviva France, after obtaining the necessary authorisations from the regulatory authorities. This large-scale operation places Aéma Groupe in the 5th position of the French insurance industry. It concretises the original ambition of Macif and Aésio Mutuelle, founders of Aéma Groupe, to build a leading mutual insurance group that now protects over 11 million French people.
‘The creation of Aéma Groupe was the culmination of the ambition of two companies, Aésio Mutuelle and Macif, to join forces to build a large-scale mutual insurance group capable of offering the broadest possible protection to its policyholders, both today and tomorrow. The acquisition of Aviva France is the first phase in this process. This transaction, which was completed in less than a year and ahead of schedule, demonstrates our ability to build a strong and innovative player that meets the growing needs of society as a whole’. - Adrien Couret - Managing Director of Aéma Groupe.
An acquisition that confirms the relevance of the Aéma Groupe model
Thanks to its economic significance and strategic importance, this transaction brings Aviva France under the French mutual insurance umbrella. Aéma Groupe thereby demonstrates its ability to expand and serve a wider range of policyholders (individuals, professionals, self-employed persons, companies) with a comprehensive range of solutions. This multi-brand, multi-network, multi-business group is strengthening its positions in all areas of insurance thanks to its complementary expertise. As a resolutely mutualist group, it will also make the voice of its members and customers heard in the public debate on social issues relating to protection and retirement.
‘We are very proud to welcome this fine company as the third pillar of Aéma Groupe, alongside Macif and Aésio. With Aviva France, we are creating a leading French mutual insurance group. From now on, Aviva France, supported by its 4,500 employees, will keep growing within our common structure. It will accomplish this while retaining its identity and its specific characteristics, with the same determination to provide increasingly relevant and sustainable insurance solutions to its 3 million policyholders, including the 760,000 members of AFER’. - Pascal Michard , Chairperson of Aéma Groupe.
New management for Aviva France
Following the acquisition, Aviva France has formed its new board of directors, which has appointed Jean-Philippe Dogneton as Chairperson and Philippe-Michel Labrosse as Chief Executive Officer of Aviva France.
‘In addition to enriching our diversity, the arrival of Aviva France within our group will enhance our diversity and gives us new responsibilities vis-à-vis the policyholders, the members and the clients we deal with on a daily basis. This acquisition will enhance the synergies of skills and expertise and the mutual know-how to enrich our offers and services. We are extremely proud and happy to welcome the Aviva France teams who share our values of solidarity and commitment’. - Jean-Philippe Dogneton , Assistant Managing Director of Aéma Groupe, Managing Director of Macif and new Chairperson of Aviva France
‘ I would like to thank the Board of Directors of Aviva France for trusting me to anchor the company to Aéma Groupe, its new parent company, and to keep it on the path to success with the support of all its employees, networks and partners’. Philippe-Michel Labrosse – Managing Director of Aviva France.
Aviva France will be rebranded with a gradual roll-out.
This acquisition involved Lazard as lead M&A advisor, Credit Suisse as financing and M&A advisor, White & Case LLP as legal advisor, Kearney for strategy, EY for accounting and financial analysis, Prim'Act for actuarial services, and Fromont Briens for employment law.
–––––––––––––––––––––––––––––––––––––––––––––––––
Key figures:
- 14.5 billion euro in turnover;
- 18,000 employees;
- 11 million policyholders;
- Property & Casualty: 5 billion euro in premium income;
- Health & Personal Protection: 3 billion euro in premium income;
- Life business: 6.5 billion euro in premium income;
- Assets under management: 195 billion euro.
Leading positions in the business lines:
- 5th largest insurance company in France;
- 2nd largest player in home and car insurance;
- 3rd largest mutual group in individual and group health;
- 5th largest player in life insurance;
- 6th largest player in asset management.
About Aéma Groupe
Aéma is the mutual insurance group formed by the merger of Aésio Mutuelle and Macif.
With more than 11 million policyholders, it employs 18,000 people
and generates a turnover of 14.5 billion euros in France.
Aéma Groupe envisions a fairer and more humane world every day by making foresight a central part of the relationship with its members, policyholders and corporate clients.
Find out more: aemagroupe.fr
View source version on businesswire.com: https://www.businesswire.com/news/home/20210930005554/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
